VEMLIDY Is indicated for the treatment of chronic hepatitis b in adults and adolescents (aged 12 years and older with body weight at least 35 kg.
Active principle: Tenofovir alafenamide fumarate
VEMLIDY®
Partner: GILEAD SCIENCES - SHTETET E BASHKUARA TE AMERIKES